Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic neutropenia]

J Palmblad1, G Elinder

  • 1Medicinska kliniken, Södersjukhuset, Stockholm. jan.palmblad@medklin.sos.sll.se

Nordisk Medicin
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Granulocyte colony-stimulating factor (G-CSF) effectively treats chronic severe neutropenia, reducing infections. However, congenital neutropenia carries risks of leukemia and osteoporosis, possibly linked to the disease or G-CSF treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaken baby syndrome and the risk of losing scientific scrutiny.

Acta paediatrica (Oslo, Norway : 1992)·2017
Same author

A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study.

Journal of internal medicine·2016
Same author

Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by ACE inhibitors.

Scandinavian journal of immunology·2014
Same author

Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.

Journal of internal medicine·2014
Same author

Plasma levels of stromal cell-derived factor-1 (CXCL12) and circulating endothelial progenitor cells in women with idiopathic heavy menstrual bleeding.

Human reproduction (Oxford, England)·2013
Same journal

[Nordisk Medicine 1929-1998. Thanks and farewell!].

Nordisk medicin·1999
Same journal

[Scientific fraud and misconduct--need for comprehensive terminology].

Nordisk medicin·1999
Same journal

[Labor-market for Scandinavian physicians in the year 2000--dearth or surplus?].

Nordisk medicin·1999
Same journal

[Internet in consultation--headed for trouble?].

Nordisk medicin·1999
Same journal

[Interpretation of questionnaires. An translation method problem].

Nordisk medicin·1999
Same journal

[Assessment of patients' health status--review of the literature and assessment methods].

Nordisk medicin·1999
See all related articles

Area of Science:

  • Hematology
  • Immunology
  • Pediatric Oncology

Context:

  • Chronic severe neutropenia is a condition characterized by abnormally low levels of neutrophils.
  • Granulocyte colony-stimulating factor (G-CSF) is a standard treatment, improving neutrophil counts and reducing infection frequency.
  • Congenital neutropenia presents unique challenges, including potential long-term risks.

Purpose:

  • To investigate the long-term risks associated with congenital neutropenia, specifically acute leukemia and osteoporosis.
  • To determine if these risks are inherent to the condition or a consequence of G-CSF treatment.
  • To establish an international registry for comprehensive data collection on neutropenia.

Summary:

  • G-CSF treatment normalizes granulocyte counts and significantly decreases infections in chronic severe neutropenia.

Related Experiment Videos

  • Congenital neutropenia is linked to increased risks of acute leukemia and osteoporosis.
  • An international registry has been created to study the natural history and treatment outcomes of neutropenia.

    • Impact:

    • Improved understanding of the natural history of congenital neutropenia.
    • Better assessment of the benefits versus risks of G-CSF therapy.
    • Facilitation of collaborative research through an international patient registry.